Resveratrol Prevents Estrogen-DNA Adduct Formation and Neoplastic Transformation in MCF-10F Cells

Overview

Journal Cancer Prev Res (Phila)

Specialty Oncology

Date 2009 Jan 14

PMID 19138946

Citations 51

Authors

Fang Lu

Muhammad Zahid

Cheng Wang

Muhammad Saeed

Ercole L Cavalieri

Eleanor G Rogan

Affiliations

Soon will be listed here.

Abstract

Exposure to estrogens is a risk factor for breast cancer. Specific estrogen metabolites may initiate breast cancer and other cancers. Genotoxicity may be caused by cytochrome P450 (CYP)-mediated oxidation of catechol estrogens to quinones that react with DNA to form depurinating estrogen-DNA adducts. CYP1B1 favors quinone formation by catalyzing estrogen 4-hydroxylation, whereas NAD(P)H quinone oxidoreductase 1 (NQO1) catalyzes the protective reduction of quinones to catechols. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces CYP1B1 expression through the aryl hydrocarbon receptor (AhR). Resveratrol has anticancer effects in diverse in vitro and in vivo systems and is an AhR antagonist that decreases CYP expression but induces NQO1 expression. The chemopreventive effect of resveratrol on breast cancer initiation was investigated in MCF-10F cells. Its effects on estrogen metabolism and formation of estrogen-DNA adducts were analyzed in culture medium by high-performance liquid chromatography, whereas its effects on CYP1B1 and NQO1 were determined by immunoblotting and immunostaining. The antitransformation effects of resveratrol were also examined. TCDD induced expression of CYP1B1 and its redistribution in the nucleus and cytoplasm. Concomitant treatment with resveratrol dose-dependently suppressed TCDD-induced expression of CYP1B1, mainly in the cytoplasm. Resveratrol dose- and time-dependently induced expression of NQO1. NQO1 is mainly in the perinuclear membrane of control cells, but resveratrol induced NQO1 and its intracellular redistribution, which involves nuclear translocation of nuclear factor erythroid 2-related factor 2. Resveratrol decreased estrogen metabolism and blocked formation of DNA adducts in cells treated with TCDD and/or estradiol. Resveratrol also suppressed TCDD and/or estradiol-induced cell transformation. Thus, resveratrol can prevent breast cancer initiation by blocking multiple sites in the estrogen genotoxicity pathway.

Citing Articles

Resveratrol Upregulates Antioxidant Factors Expression and Downmodulates Interferon-Inducible Antiviral Factors in Aging.

Fernandes I, Oliveira L, Andrade M, Alberca R, Lima J, de Sousa E Int J Mol Sci. 2025; 26(5).

PMID: 40076963 PMC: 11900160. DOI: 10.3390/ijms26052345.

The Aryl Hydrocarbon Receptor and Its Crosstalk: A Chemopreventive Target of Naturally Occurring and Modified Phytochemicals.

Szaefer H, Licznerska B, Baer-Dubowska W Molecules. 2024; 29(18).

PMID: 39339278 PMC: 11433792. DOI: 10.3390/molecules29184283.

Investigating the Molecular Mechanisms of Resveratrol in Treating Cardiometabolic Multimorbidity: A Network Pharmacology and Bioinformatics Approach with Molecular Docking Validation.

Gong W, Sun P, Li X, Wang X, Zhang X, Cui H Nutrients. 2024; 16(15).

PMID: 39125368 PMC: 11314475. DOI: 10.3390/nu16152488.

Upregulation of CYP1B1 by hypoxia is mediated by ERα activation in breast cancer cells.

Min J, Lee G, Khanal T, Jin S, Lee S, Kim H Am J Cancer Res. 2022; 12(6):2798-2816.

PMID: 35812067 PMC: 9251700.

Endogenous estrogens-breast cancer and chemoprevention.

Starek-Swiechowicz B, Budziszewska B, Starek A Pharmacol Rep. 2021; 73(6):1497-1512.

PMID: 34462889 PMC: 8599256. DOI: 10.1007/s43440-021-00317-0.

References

Cavalieri E, Rogan E . Catechol quinones of estrogens in the initiation of breast, prostate, and other human cancers: keynote lecture. Ann N Y Acad Sci. 2007; 1089:286-301. DOI: 10.1196/annals.1386.042. View

Aziz M, Kumar R, Ahmad N . Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol. 2003; 23(1):17-28. View

Fang J, Lu M, Chen Z, Li Y, Yang L, Wu L . Antioxidant effects of resveratrol and its analogues against the free-radical-induced peroxidation of linoleic acid in micelles. Chemistry. 2002; 8(18):4191-8. DOI: 10.1002/1521-3765(20020916)8:18<4191::AID-CHEM4191>3.0.CO;2-S. View

Park S, Zhao H, Spitz M, Grossman H, Wu X . An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res. 2003; 536(1-2):131-7. DOI: 10.1016/s1383-5718(03)00041-x. View

Lee J, Li J, Johnson D, Stein T, Kraft A, Calkins M . Nrf2, a multi-organ protector?. FASEB J. 2005; 19(9):1061-6. DOI: 10.1096/fj.04-2591hyp. View

Zahid M, Gaikwad N, Rogan E, Cavalieri E . Inhibition of depurinating estrogen-DNA adduct formation by natural compounds. Chem Res Toxicol. 2007; 20(12):1947-53. DOI: 10.1021/tx700269s. View

Hayes C, Spink D, Spink B, Cao J, Walker N, Sutter T . 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci U S A. 1996; 93(18):9776-81. PMC: 38505. DOI: 10.1073/pnas.93.18.9776. View

Vargas M, Pehar M, Cassina P, Martinez-Palma L, Thompson J, Beckman J . Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival. J Biol Chem. 2005; 280(27):25571-9. DOI: 10.1074/jbc.M501920200. View

Lu F, Zahid M, Saeed M, Cavalieri E, Rogan E . Estrogen metabolism and formation of estrogen-DNA adducts in estradiol-treated MCF-10F cells. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin induction and catechol-O-methyltransferase inhibition. J Steroid Biochem Mol Biol. 2007; 105(1-5):150-8. PMC: 1986824. DOI: 10.1016/j.jsbmb.2006.12.102. View

10.

Spink D, Spink B, Cao J, DePasquale J, Pentecost B, Fasco M . Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis. 1998; 19(2):291-8. DOI: 10.1093/carcin/19.2.291. View

11.

Muskhelishvili L, Thompson P, Kusewitt D, Wang C, Kadlubar F . In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J Histochem Cytochem. 2001; 49(2):229-36. DOI: 10.1177/002215540104900210. View

12.

Shimada T, Hayes C, Yamazaki H, Amin S, Hecht S, Guengerich F . Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res. 1996; 56(13):2979-84. View

13.

Singh S, Chakravarti D, Edney J, Hollins R, Johnson P, West W . Relative imbalances in the expression of estrogen-metabolizing enzymes in the breast tissue of women with breast carcinoma. Oncol Rep. 2005; 14(4):1091-6. View

14.

Dickson R, Stancel G . Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr. 2000; (27):135-45. DOI: 10.1093/oxfordjournals.jncimonographs.a024237. View

15.

Spink D, Hayes C, Young N, Christou M, Sutter T, Jefcoate C . The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: evidence for induction of a novel 17 beta-estradiol 4-hydroxylase. J Steroid Biochem Mol Biol. 1994; 51(5-6):251-8. DOI: 10.1016/0960-0760(94)90037-x. View

16.

Carnell D, Smith R, Daley F, Barber P, Hoskin P, Wilson G . Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int J Radiat Oncol Biol Phys. 2004; 58(2):500-9. DOI: 10.1016/j.ijrobp.2003.09.064. View

17.

Talalay P, Dinkova-Kostova A, Holtzclaw W . Importance of phase 2 gene regulation in protection against electrophile and reactive oxygen toxicity and carcinogenesis. Adv Enzyme Regul. 2003; 43:121-34. DOI: 10.1016/s0065-2571(02)00038-9. View

18.

Zahid M, Saeed M, Lu F, Gaikwad N, Rogan E, Cavalieri E . Inhibition of catechol-O-methyltransferase increases estrogen-DNA adduct formation. Free Radic Biol Med. 2007; 43(11):1534-40. PMC: 2096412. DOI: 10.1016/j.freeradbiomed.2007.08.005. View

19.

Surh Y . Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003; 3(10):768-80. DOI: 10.1038/nrc1189. View

20.

Russo J, Fernandez S, Russo P, Fernbaugh R, Sheriff F, Lareef H . 17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells. FASEB J. 2006; 20(10):1622-34. DOI: 10.1096/fj.05-5399com. View